Myocarditis after COVID‐19 mRNA vaccination in Australia

Description

Vaccination of 12–16‐year‐old adolescents with Comirnaty (tozinameran, Pfizer–BioNTech) and Spikevax (elasomeran, Moderna) was approved in Australia on 22 July 2021 and 3 September 2021 respectively.

In this report, we describe the initial diagnosis, imaging findings, and short term outcomes for adolescents who presented with COVID‐19 vaccine‐associated myocarditis to the Monash Children’s Hospital, a tertiary centre in Melbourne with a paediatric cardiology service.

The Monash Health human research ethics committee (QA/81618/MonH‐2021‐291293) approved the study.

This MJA research letter shares more.

 

Learning Outcomes

1. Explain key components of the research.
2. List main findings.
3. Recognise changes in management in response to the research.

 

Authors: Suraj K Varma, Ari E Horton, Anna L Taylor, Michael R Ditchfield, Sarah A Hope and Srinidhi JV Rao

Article Type: Research letter